Overview
Adjusted EPS for Q4 beat analyst expectations
Outlook
Verastem expects cash runway into first half of 2027
Result Drivers
FDA APPROVAL IMPACT - AVMAPKI FAKZYNJA CO-PACK generated $17.5 mln in Q4 revenue following accelerated FDA approval
INCREASED EXPENSES - Higher operating expenses due to commercialization costs and increased R&D spending
Company press release: ID:nBw9DVShna
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Adjusted EPS
Beat
-$0.48
-$0.53 (9 Analysts)
Q4 Net Income
-$32.92 mln
Q4 Income from Operations
-$41.47 mln
Q4 Operating Expenses
$59.009 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Verastem Inc is $17.00, about 199.3% above its March 3 closing price of $5.68
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
